FDA nod to MYQORZO for obstructive hypertrophic cardiomyopathy
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
The system is intended for some of the tiniest patients—premature infants weighing as little as two pounds
GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
SGX945 delivered beneficial effects in 7 of 8 patients suffering from painful oral ulcers
At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
The move strengthens GBL’s clinical-stage presence in the United States
Subscribe To Our Newsletter & Stay Updated